Controlled Substances and Emergency Response Fact Sheet: Frequently Asked Questions
ASPR’s BARDA Funds its First Marburg Virus Vaccine Development
To increase national health security against biothreats and protect public health, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, awarded an initial two-year, $10 million contract to Public Health Vaccines, LLC of Cambridge, Massachusetts, to develop a potential vaccine against Marburg virus. No licensed vaccine for this virus exists today.
The Marburg virus is part of the family of hemorrhagic fever viruses that includes Ebola. The virus causes a similar illness to that of Ebola, and occurs most often in Africa. The Marburg virus was recognized in 1967 and since then multiple outbreaks have occurred with high mortality rates, most recently in 2017.